Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit (Details Textual)

v3.19.1
Stockholders' Deficit (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Mar. 31, 2018
Feb. 22, 2019
Feb. 22, 2019
Jan. 31, 2019
Jan. 22, 2019
Jan. 18, 2019
Mar. 31, 2019
Mar. 31, 2018
Shares of common stock issued       22,311 250,000   93,100  
Warrants for purchase       $ 65,130 $ 300,000   $ 93,100  
Outstanding options intrinsic value             $ 188,927  
Options granted             508,100  
Stock options issued             $ 1,173,000  
Common stock exercise price       $ 4.99 $ 3.75   $ 6.25  
Interest and financing charges             $ 51,678
Weighted average remaining vesting period             2 years 8 months 26 days  
R&D Expense [Member]                
Equity-based compensation expense             $ 129,150 $ 69,161
G&A Expense [Member]                
Equity-based compensation expense             3,381,987  
IPO [Member]                
Initial public offering, description   The Company concluded the Follow-on Offering of 2,475,000 shares of common stock and warrants to purchase 1,856,250 shares of common stock at an exercise price of $4.0625 per share. The shares of common stock and accompanying warrants were sold to the public at a price of $3.25 per share and three quarters warrant. The underwriters were granted an over-allotment option to purchase up to 371,250 shares of common stock and 278,437 warrants at a price of $3.25 per share of common stock and three quarters warrant. The underwriters partially exercised their over-allotment option by purchasing 370,000 shares of common stock and warrants to purchase 277,500 shares common stock. Gross proceeds of the offering, totaled $9,246,249, which after offering expenses, resulted in net proceeds of $8,195,673.            
Consultant [Member]                
Common stock issued price             $ 154,854  
Common stock issued, shares             93,750  
Officers and Director [Member]                
Shares of common stock issued 292,309              
Equity-based compensation expense $ 1,461,545              
Common stock issued price         $ 468,750   $ 581,875  
Warrants [Member]                
Shares of common stock issued     2,132,750     300,000 2,166  
Warrants for purchase   $ 2,133,750 $ 2,133,750     $ 300,000 $ 2,166  
Common stock exercise price             $ 0.005  
Exercise price   $ 4.0625 $ 4.0625     $ 3.75    
Common stock issued price             $ 12  
Recognized a non-cash expense           441,763    
Warrant purchase, description             The Company issued 93,100 warrants with an exercise price of $6.25 per share of common stock were exercised for $581,875, 125,000 warrants with an exercise price of $3.75 per share of common stock were exercised for $468,750, 2,166 warrants with an exercise price of $0.005 per share of common stock were exercised for $12, and 240,130 warrants were exercised cashlessly for the issue of 147,311 shares of common stock. The total received in exercise fees for exercise of warrants was $1,050,637, resulting in the issue of a total of 367,577 shares of common stock on the exercise of 460,396 warrants.